Nordic Nanovector

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Nordic Nanovector’s mission is to develop and commercialize innovative targeted therapies to improve the lives of patients suffering from cancer and other serious diseases.

Nordic Nanovector’s vision is to become a leader in developing therapeutic solutions and technologies to improve the lives of patients.

Nordic Nanovector has been recognized over the years for its innovative approach to drug development, selection of high quality medicines and commitment to corporate social responsibility. The company received the 2019 Red Herring Top 100 Global Award and was ranked in the EU TOP 10 category for oncology innovation in the 2017 EU Business Awards.